RxDoctor Payments Data

Brandon Thurow, MD

Family Medicine · Conway, ARNPI 1033346358

Payments from drug & device makers

$9,666in general payments, 2019–2025

Across 603 payments — averaging $16.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Pfizer$1K
  • AbbVie$801
  • Lilly USA, LLC$753
  • Bayer$586
  • Novo Nordisk$582
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$9,61099%
  • Education$571%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,666 in reported general payments places this provider in the 90th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$174,659
Medicare patients
257
Services billed
2,998

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide141$154,365
EliquisApixaban400$147,450
Trelegy ElliptaFluticasone/Umeclidin/Vilanter94$75,043
MounjaroTirzepatide64$67,426
JardianceEmpagliflozin86$57,592
EntrestoSacubitril/Valsartan85$34,047
FarxigaDapagliflozin Propanediol48$29,821
KerendiaFinerenone41$25,562
JanuviaSitagliptin Phosphate65$19,301
XareltoRivaroxaban39$17,975
Megestrol Acetate62$13,595
Nurtec OdtRimegepant Sulfate12$12,842
Methenamine Hippurate141$11,839
MyrbetriqMirabegron46$10,853
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$9,800

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$1,018$160,292412 claims
Novo NordiskOzempic$582$154,365141 claims
GSKTrelegy Ellipta, Breo Ellipta$525$84,111116 claims
Lilly USA, LLCMounjaro$753$67,42664 claims
Boehringer IngelheimJardiance, Spiriva Respimat$231$65,969101 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$1,780$47,49385 claims
NovartisEntresto$139$34,04785 claims
BayerKerendia$586$25,56241 claims
MerckJanuvia, Dulera$158$23,32876 claims
Johnson & JohnsonXarelto$239$17,97539 claims
AbbVieLinzess, Synthroid$801$12,02082 claims
Astellas Pharma US IncMyrbetriq$144$10,85346 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Conway

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →